Suppr超能文献

N3期鼻咽癌患者诱导化疗后行调强放疗及辅助化疗的长期疗效

Long-term outcomes of induction chemotherapy followed by intensity-modulated radiotherapy and adjuvant chemotherapy in nasopharyngeal carcinoma patients with N3 disease.

作者信息

Niu Xiaoshuang, Xue Fen, Liu Peiyao, Hu Chaosu, He Xiayun

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.

出版信息

Transl Oncol. 2021 Dec;14(12):101216. doi: 10.1016/j.tranon.2021.101216. Epub 2021 Sep 14.

Abstract

OBJECTIVES

To evaluate long-term outcomes of induction chemotherapy (IC) followed by intensity-modulated radiotherapy (IMRT) and adjuvant chemotherapy (AC) in nasopharyngeal carcinoma (NPC) patients with N3 disease.

MATERIALS AND METHODS

From September 2005 to August 2016, 143 patients confirmed NPC with the 8th AJCC/UICC staging criteria N3 were reviewed. All patients received IC followed by IMRT and AC.

RESULTS

After a median follow-up of 67 months, the 5-year and 10-year overall survival (OS), progression-free survival (PFS), distant metastasis free survival (DMFS), local progression-free survival (LPFS) and regional progression-free survival (RPFS) were 75.7% and 61.6%, 61.2% and 53.4%, 73.1% and 72.1%, 92.4% and 87%, 88.9% and 81.8%, respectively. Multivariate analyses indicated that T stage (P = 0.001) appeared to be prognostic factors for OS. T stage (P = 0.001 and P = 0.002) and neck lymph node necrosis (P = 0.015 and P = 0.045) were independent predictors of PFS and DMFS. The acute toxicities were mainly grade 1/2 hematologic toxicities in patients treated with IC+IMRT+AC, and severe toxicities were uncommon.

CONCLUSIONS

IC followed by IMRT and AC achieved satisfactory long-term survival outcomes in NPC patients with N3 disease. Neck lymph node necrosis and late T stage served as predictors of poor prognosis for patients.

摘要

目的

评估诱导化疗(IC)联合调强放疗(IMRT)及辅助化疗(AC)对N3期鼻咽癌(NPC)患者的长期疗效。

材料与方法

回顾性分析2005年9月至2016年8月期间确诊的143例符合第8版美国癌症联合委员会/国际抗癌联盟(AJCC/UICC)分期标准的N3期NPC患者。所有患者均接受IC后序贯IMRT及AC治疗。

结果

中位随访67个月后,5年和10年总生存率(OS)、无进展生存率(PFS)、无远处转移生存率(DMFS)、无局部进展生存率(LPFS)和无区域进展生存率(RPFS)分别为75.7%和61.6%、61.2%和53.4%、73.1%和72.1%、92.4%和87%、88.9%和81.8%。多因素分析表明,T分期(P = 0.001)似乎是OS的预后因素。T分期(P = 0.001和P = 0.002)及颈部淋巴结坏死(P = 0.015和P = 0.045)是PFS和DMFS的独立预测因素。IC+IMRT+AC治疗患者的急性毒性主要为1/2级血液学毒性,严重毒性不常见。

结论

IC联合IMRT及AC治疗在N3期NPC患者中取得了令人满意的长期生存结果。颈部淋巴结坏死和晚期T分期是患者预后不良的预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f6d/8450248/eec4e5204a29/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验